Global Respiratory Disease Testing Market 2015-2019
About respiratory disease testing
The respiratory system of the body plays a vital role in eliminating carbon dioxide and toxic wastes, regulates the temperature, and establishes a stabilized blood acid-alkaline balance. Respiratory diseases such as asthma, bronchitis, COPD occur due to acute or chronic defects in the respiratory system. The respiratory testing devices help in detecting chronic or acute respiratory diseases; therefore, the necessary treatment can be provided to people suffering from respiratory damages.
Respiratory tests such as imaging, spirometry, peak flow test, blood gas test, lung volume, and few other tests are used to diagnose the respiratory disease. Globally, there has been growing incidences of respiratory diseases such as asthma and COPD. Around 235 million people globally are suffering from asthma, and there have been around 3 million deaths worldwide due to COPD. This indicates an alarming increase in the respiratory disorders worldwide due to high pollution and increased tobacco consumption.
These factors result in increased demand for the respiratory testing devices and propel the market growth.
Technavio's analysts forecast the global respiratory disease testing market to grow at a CAGR of 7.46% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global respiratory disease testing market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of testing devices used to diagnose acute and chronic respiratory diseases.
The market is segmented based on the type of test:
Technavio Announces the Publication of its Research Report – Global Respiratory Disease Testing Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Respiratory Disease Testing Market: Alere, CareFusion, COSMED, Nihon Kohden, Philips Healthcare and Smiths Medical
Other Prominent Vendors in the market are: Diamedix, Affymetrix, Seegene, Cepheid, NDD Medical Technologies, COSMED, Abbott, F. Hoffmann-La Roche, Siemens Healthcare, Instrumentation Laboratories, Covidien, SDI Diagnostics, and Futuremed America.
Commenting on the report, an analyst from Technavio’s team said: “Multiplex devices are used to detect two or more respiratory disease-causing pathogens at the same time. These systems provide sensitive and comprehensive diagnosis, positively influencing patient care and the drug delivery system. RespiFinder RG panel by QIAGEN is one of the multiplex device that can detect 21 pathogens causing respiratory diseases such as acute respiratory tract infection in four hours.”
According to the report, the consumption of tobacco, particularly in the form of cigarettes, is a major cause of chronic respiratory diseases worldwide. Annually, tobacco consumption results in about six million deaths worldwide. Of this number, about five million individuals die due to direct tobacco consumption while 0.6 million people die due to passive smoking. Research studies report that tobacco consumption is high in developing countries compared to developed countries.
Further, the report states that automation in respiratory disease testing is fast gaining momentum due to its limited turnaround time. However, automated instruments are associated with high purchase, installation, maintenance, and upgrading costs. The availability of funds for the development and maintenance of these testing devices is low. Coupled with this, the lack of standards for comparison is lowering the accuracy and specificity of tests for the detection of disease-causing pathogens.
Alere, CareFusion, COSMED, Nihon Kohden, Philips Healthcare, Smiths Medical, Diamedix, Affymetrix, Seegene, Cepheid, NDD Medical Technologies, COSMED, Abbott, F. Hoffmann-La Roche, Siemens Healthcare, Instrumentation Laboratories, Covidien, SDI Diagnostics, Futuremed America.